Ciplas Stempeutics gets US patent for stemcell product

Drug used to treat limb disorder

Mumbai, March 4:

Stempeutics Research has received a process patent from the United States Patent and Trademarks Office for its novel stem cell-based drug Stempeucel.

The company is part of the Manipal Education and Medical Group and drugmaker Cipla entered into a joint alliance with it in 2009.

The drug will initially be used for the treatment of Critical Limb Ischemia (CLI), the companies said in a joint note, adding that the treatment option directly addresses the root cause of the disease, unlike others that treat the symptoms and not the disease.

CLI is a progressive form of peripheral arterial disease that blocks arteries in the lower extremities of the body, resulting in reduced blood flow.

It is a debilitating disease which affects patients with severe pain in the feet or toes, besides the development of sores and wounds, the note said.

If left untreated, patients may have to undergo amputation of the affected limb, it added.

Stempeutics has also submitted its applications to the regulatory Drug Controller General of India (DCGI) to obtain marketing authorisation for Stempeucel.

The availability of the product in the local market is subject to DCGI approvals.

Follow this link:
Ciplas Stempeutics gets US patent for stemcell product

Related Posts